-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 J2OvCU7Ctq87tqwiYbmh6hJQli2p1LQZEUZn5wq94S7z60OTeNMdtCDUHhRqS6Qi
 ZLxVgbx4ox/Tgqs/A2QBDQ==

<SEC-DOCUMENT>0001010549-09-000671.txt : 20091001
<SEC-HEADER>0001010549-09-000671.hdr.sgml : 20091001
<ACCEPTANCE-DATETIME>20091001105024
ACCESSION NUMBER:		0001010549-09-000671
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20091001
DATE AS OF CHANGE:		20091001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-152272
		FILM NUMBER:		091097499

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>cph424b3100109.htm
<TEXT>
<html>
    <head>
        <title></title>
    </head>

    <body style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'">
        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 204px; FONT-FAMILY: 'COURIER NEW'" align="right"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'">Filed under Rule 424(b)(3)</font></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'COURIER NEW'" align="right"><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">&nbsp;Registration No.: 333-152272</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10.5pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="center"><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">PROSPECT</font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">US SUPPLEMENT NO. </font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">5</font></b> <b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">DATED
        </font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">OCTOBER </font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">1</font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">, 2009</font></b></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10.5pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="center"><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">TO PROSPECTUS DATED </font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">AUGUST 12</font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">, 200</font></b><b><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">8</font></b></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'COURIER NEW'" align="center"><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">Prospectus <br>
        &nbsp; </font></b></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'COURIER NEW'" align="center"><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">China Pharma Holdings, Inc.</font></b><br>
        &nbsp;</p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'COURIER NEW'" align="center">
        <b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">6</font></b><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">,</font></b><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">4</font></b><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">5</font></b><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">0</font></b><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">
        ,</font></b><b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">000</font></b> <b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">Shares of</font></b> <b><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'TIMES NEW ROMAN'">Common Stock</font></b></p>

        <p></p>

        <p style="FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR First Line Ind .5 Inch" align="justify">This Prospectus Supplement No.&nbsp;5 supplements and amends the prospectus dated August 12, 2008, as supplemented and amended by Prospectus Supplement No. 1 dated March 23, 2009, Prospectus Supplement No. 2 dated May 4, 2009, Prospectus Supplement No. 3 dated June 30, 2009, and Prospectus Supplement
        No. 4 dated September 28, 2009, which we refer to collectively as the Prospectus. This prospectus relates to the offer for sale of up to 6,450,000 shares of our common stock by certain existing holders of the securities, referred to as Selling Security Holders.</p>

        <p style="FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR First Line Ind .5 Inch" align="justify">On October 1, 2009, we filed with the Securities and Exchange Commission our Current Report on Form 8-K. A copy of such Current Report on Form 8-K is attached to and constitutes an integral part of this Prospectus Supplement No.&nbsp;5.</p>

        <p style="FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR First Line Ind .5 Inch" align="justify">This Prospectus Supplement No.&nbsp;5 should be read in conjunction with the Prospectus, which is to be delivered with this Prospectus Supplement No.&nbsp;5. This Prospectus Supplement No.&nbsp;5 is qualified by reference to the Prospectus except to the extent that the information in this Prospectus
        Supplement No.&nbsp;5 supersedes the information contained in the Prospectus.</p>

        <p style="FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR First Line Ind .5 Inch" align="justify"><b>In reviewing the Prospectus and</b> <b>this Prospectus Supplement No.&nbsp;</b> <b>5</b><b>, you should carefully consider the risks under &ldquo;Risk Factors&rdquo; beginning on page</b> <b>7</b> <b>of the Prospectus, dated</b> <b>August</b> <b>12, 2008, as updated by the risk factors discussed in
        Item&nbsp;1A</b> <b>of Part I</b> <b>of the Form 10-</b><b>K</b> <b>dated March 17, 2009</b><b>.</b></p>

        <p style="FONT-SIZE: 10pt; TEXT-INDENT: 0.5in; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR First Line Ind .5 Inch" align="justify"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this Prospectus Supplement No.&nbsp;</b> <b>5</b> <b>is truthful or complete. Any representation to the contrary is a criminal
        offense.</b></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="left">&nbsp;</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" align="center"><b>The date of this Prospectus Supplement No.&nbsp;</b> <b>5</b> <b>is</b> <b>October 1</b><b>, 2009</b><b>.</b></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="center">&nbsp;</p>
        <!-- PAGE BREAK  -->

        <div title="EE+ Page Break" style="FONT-SIZE: 1pt; PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 1px">
            <hr width="100%" color="#000000" noshade size="2">
        </div>

        <p>&nbsp;</p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="4"><strong>UNITED STATES<br>
        SECURITIES AND EXCHANGE COMMISSION</strong></font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">Washington, D.C. 20549</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 16pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="6"><strong>FORM 8-K</strong></font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'">CURRENT REPORT</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center">PURSUANT TO SECTION 13 OR 15(d) of the</p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center">SECURITIES EXCHANGE ACT OF 1934</p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="2">October 1, 2009</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><b><font style="FONT-SIZE: 18pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="5">China Pharma Holdings, Inc</font></b></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 12pt; FONT-FAMILY: 'TIMES NEW ROMAN'">------------------------------</font></p>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'">(Exact name of registrant as specified in its charter)</font></p>

        <p align="center"></p>

        <p></p>

        <p></p>

        <table cellspacing="0" cellpadding="0" width="100%" border="0">
            <tr>
                <td colspan="6">
                    <p align="center"><font size="2"><strong>Delaware</strong> </font></p>
                </td>
            </tr>

            <tr>
                <td colspan="6">
                    <p align="center"><font size="2">(State or other jurisdiction of incorporation)</font></p>
                </td>
            </tr>

            <tr>
                <td width="92">
                </td>

                <td width="363">&nbsp;</td>

                <td width="23">
                </td>

                <td width="402">
                </td>

                <td colspan="2">
                </td>
            </tr>

            <tr height="18">
                <td width="92">
                </td>

                <td width="363">
                    <p align="center"><font size="2"><strong>000-29532</strong></font></p>
                </td>

                <td width="23">
                </td>

                <td width="402">
                    <p align="center"><font size="2"><strong>73-1564807</strong></font></p>
                </td>

                <td colspan="2">
                </td>
            </tr>

            <tr>
                <td width="92">
                </td>

                <td width="363">
                    <p align="center"><font size="2">(Commission File Number)</font></p>
                </td>

                <td width="23">
                </td>

                <td width="402">
                    <p align="center"><font size="2">&nbsp;(IRS Employer Identification Number)</font></p>
                </td>

                <td colspan="2">
                </td>
            </tr>

            <tr>
                <td width="92">
                </td>

                <td width="363">&nbsp;</td>

                <td width="23">
                </td>

                <td width="402">
                </td>

                <td colspan="2">
                </td>
            </tr>

            <tr>
                <td colspan="6">
                    <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="2"><strong>2nd Floor, No. 17, Jinpan Road</strong></font></p>
                </td>
            </tr>

            <tr>
                <td colspan="6">
                    <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="2"><strong>Haikou, Hainan Province, China</strong></font></p>
                </td>
            </tr>

            <tr>
                <td colspan="6">
                    <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="2">(Address of Principal Executive Offices)</font></p>
                </td>
            </tr>

            <tr>
                <td colspan="6">&nbsp;</td>
            </tr>

            <tr>
                <td colspan="6">
                    <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px; FONT-FAMILY: 'TIMES NEW ROMAN'" align="center"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'TIMES NEW ROMAN'" size="2"><strong>86-898-66811730</strong> </font></p>
                </td>
            </tr>

            <tr>
                <td colspan="6">
                    <p align="center"><font size="2">(Registrant's telephone number, including area code)</font></p>
                </td>
            </tr>
        </table>
        <br>
        <br>


        <p></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
        [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
        [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
        [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

        <div title="EE+ Page Break" style="FONT-SIZE: 1pt; PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 1px">
            <hr width="100%" color="#000000" size="2">
        </div>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10.5pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify">&nbsp;</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify"><b>Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995</b>&nbsp;</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify"><i>Information included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other
        factors which may cause the Company's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company's future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the
        negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections included in these forward-looking statements will come to pass. The Company's actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company
        undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.</i></p>

        <p></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify"><b>Item 8.01. Other Events.</b></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR"></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify">On September 28, 2009, the NYSE Amex LLC (the &ldquo;<u>Exchange</u>&rdquo;) informed China Pharma Holdings, Inc., a Delaware corporation (the &ldquo;<u>Company</u>&rdquo;) that the Exchange had authorized the listing of the Company&rsquo;s common stock on the Exchange.&nbsp;&nbsp; On the same date, the Company issued a press release announcing
        that it has received approval to list its securities on the Exchange. A copy of the press release is furnished as Exhibit 99.1 hereto.</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR"></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify">The Company&rsquo;s common stock ceased trading on the OTC Bulletin Board (the &ldquo;<u>OTCBB</u>&rdquo;) and commenced trading on the Exchange on September 30, 2009 under the ticker symbol &ldquo;CPHI&rdquo;.</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR"></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="left"><b>Item</b> <b>9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits&nbsp;</b></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="left">(d)&nbsp;Exhibits</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="left"></p>

        <p></p>

        <table cellspacing="0" cellpadding="0" width="100%" border="0">
            <tr valign="bottom">
                <td align="right" width="1%"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td width="11%">
                    <p align="left"><font face="Times New Roman, Times, serif" size="2"><u>Exhibit No.</u></font></p>
                </td>

                <td align="left" width="3%"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td align="left" width="83%"><font face="Times New Roman, Times, serif" size="2"><u>Exhibit Title</u></font></td>

                <td align="left" width="1%"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td align="left" width="1%"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>
            </tr>

            <tr>
                <td align="right">
                </td>

                <td>&nbsp;</td>

                <td align="left">
                </td>

                <td align="left">
                </td>

                <td align="left">
                </td>

                <td align="left">
                </td>
            </tr>

            <tr valign="bottom">
                <td align="right"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td>
                    <p align="left"><font face="Times New Roman, Times, serif" size="2">99.1</font></p>
                </td>

                <td align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td align="left"><font face="Times New Roman, Times, serif" size="2">Press Release of China Pharma Holdings, Inc. dated September 28, 2009</font></td>

                <td align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>
            </tr>
        </table>
        <br>
        <br>


        <p></p>
        <!-- NEXT PAGE SECTION BREAK  -->

        <div title="EE+ Page Break" style="FONT-SIZE: 1pt; PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 1px">
            <hr width="100%" color="#000000" noshade size="2">
        </div>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" align="center"><b>Signature</b></p>

        <p></p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify">Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.</p>

        <p style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; EEPStyleName: Para Just 10pt TNR" align="justify"></p>

        <p></p>

        <table cellspacing="0" cellpadding="0" width="100%" border="0">
            <tr valign="bottom">
                <td align="left" colspan="6"><font face="Times New Roman, Times, serif" size="2">China Pharma Holdings, Inc.&nbsp;&nbsp;&nbsp;&nbsp;</font></td>
            </tr>

            <tr valign="bottom">
                <td align="left" colspan="6"><font face="Times New Roman, Times, serif" size="2">Date: October 1, 2009&nbsp;&nbsp;&nbsp;&nbsp;</font></td>
            </tr>

            <tr>
                <td align="left" width="118">&nbsp;</td>

                <td align="left" width="445">
                </td>

                <td align="left">
                </td>

                <td align="left">
                </td>

                <td align="left">
                </td>

                <td align="left">
                </td>
            </tr>

            <tr valign="bottom">
                <td style="BORDER-BOTTOM: black 1px solid" align="left" width="118"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; s/ Zhilin Li</font></td>

                <td align="left" width="445"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td align="left">
                </td>

                <td align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>

                <td align="left"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font></td>
            </tr>

            <tr valign="bottom">
                <td align="left" colspan="6"><font face="Times New Roman, Times, serif" size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zhilin Li&nbsp;&nbsp;&nbsp;&nbsp;</font></td>
            </tr>

            <tr valign="bottom">
                <td align="left" colspan="6"><font face="Times New Roman, Times, serif" size="2">&nbsp;President and CEO&nbsp;&nbsp;&nbsp;&nbsp;</font></td>
            </tr>
        </table>
        <br>
        <br>
        <br>
        <br>


        <p></p>

        <p>&nbsp;</p>

        <p>&nbsp;</p>

        <p>&nbsp;</p>

        <div title="EE+ Page Break" style="FONT-SIZE: 1pt; PAGE-BREAK-AFTER: always; WIDTH: 100%; HEIGHT: 1px">
            <hr width="100%" color="#000000" size="2">
        </div>

        <p style="MARGIN-TOP: 0pt; FONT-SIZE: 10.5pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Arial, Helvetica, sans-serif">Exhibit 99.1</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="center"><b><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'ARIAL'">China Pharma Holdings, Inc. </font></b><b><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'ARIAL'">Announces </font></b></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="center"><b><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'ARIAL'">Approval for </font></b><b><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'ARIAL'">NYSE</font></b> <b><font style="FONT-SIZE: 14pt; FONT-FAMILY: 'ARIAL'">Amex Listing</font></b></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">HAIKOU CITY, China, September 28, 2009</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval to
        list its securities on NYSE</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">Amex.</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">China Pharma expects to begin trading on</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">NYSE Amex</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">on Wednesday, September 30, 2009. In connection with its</font>
        <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">listing on NYSE Amex, the Company&rsquo;s ticker symbol will change to &ldquo;CPHI&rdquo;</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">from &ldquo;CPHI.OB&rdquo;.</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">Ms. Zhilin Li, CEO and President of China Pharma, commented, "It is a major milestone to move to NYSE Amex,</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">and we are</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">proud of</font>
        <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">our</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">fulfillment of this target.</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">We believe that NYSE Amex</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">provides excellent exposure for companies from</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">emerging
        markets,</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">such as ours. This step</font> <font style="FONT-SIZE: 10pt; COLOR: #000000; FONT-FAMILY: 'ARIAL'">underscores our commitment to generating long-term value for our shareholders."</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><b><font style="FONT-FAMILY: 'ARIAL'">About China Pharma Holdings, Inc.</font></b></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><font style="FONT-FAMILY: 'ARIAL'">China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by
        market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical &amp; Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China
        Pharma Holdings, Inc., please visit <u><font color="#3333ff">http://www.chinapharmaholdings.com</font></u></font> <font style="FONT-FAMILY: 'ARIAL'">.</font></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><i><font style="FONT-FAMILY: 'ARIAL'">Safe Harbor Statement</font></i></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><i><font style="FONT-FAMILY: 'ARIAL'">Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are
        forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other
        information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.<br>
        &nbsp; </font></i></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><b><font style="FONT-FAMILY: 'ARIAL'">For more information, please contact:</font></b></p>

        <p></p>

        <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 0in; TEXT-INDENT: 0px" align="justify"><font style="FONT-FAMILY: 'ARIAL'">&nbsp;&nbsp;&nbsp;&nbsp; China Pharma Holdings, Inc.<br>
        &nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp;+86-898-6681-1730<br>
        &nbsp;&nbsp;&nbsp;&nbsp; Email: </font><u><font color="#3333ff">hps@chinapharmaholdings.com<br>
        </font></u>&nbsp;<br>
        <font style="FONT-FAMILY: 'ARIAL'">&nbsp;&nbsp;&nbsp;&nbsp; ICR, Inc.<br>
        &nbsp;&nbsp;&nbsp;&nbsp; Christine Duan<br>
        &nbsp;&nbsp;&nbsp;&nbsp; Tel: +1-203-682-8200</font></p>
    </body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
